Literature DB >> 11350096

Predictors of long-term survival after valve replacement for chronic aortic regurgitation; is M-mode echocardiography sufficient?

R Corti1, C Binggeli, M Turina, R Jenni, T F Lüscher, J Turina.   

Abstract

AIMS: The clinical importance of pre-operative and follow-up echocardiographic studies in patients operated on for chronic severe aortic valve regurgitation is still a matter of debate. The prognostic significance of M-mode echocardiography has never been directly compared with clinical and angiographic data. METHODS AND
RESULTS: Univariate and multivariate analyses of cumulative survival were performed for clinical, echocardiographic and angiographic data of 125 patients operated on between 1975 and 1983, and followed for 13.3+/-6.4 years. Ten and 20 year survival rates were 77% and 48%, respectively. Age, NYHA class, angiographic volumes, ejection fraction, as well as M-mode echocardiographic end-systolic dimension and shortening fraction were the main pre-operative prognostic parameters for long-term survival. In a multivariate analysis the angiographic end-systolic volume index, age and preoperative NYHA class were independent pre-operative prognostic variables of long-term survival. A postoperative reduction in end-diastolic dimension of >20% predicted a significantly better late survival (74% vs 44% after 20 years, P<0.001).
CONCLUSIONS: Age, pre-operative NYHA class and left ventricular systolic function are the main determinants of long-term survival after valve replacement for chronic aortic regurgitation. Despite a slightly lower predictive value of echocardiography when compared to angiography, it appeared sufficient for everyday clinical decision making for valve replacement. Echocardiography within 6 months postoperatively is able to detect recovery of left ventricular function, and enables additional risk-stratification, regardless of pre-operative findings. Copyright 2001 The European Society of Cardiology.

Entities:  

Mesh:

Year:  2001        PMID: 11350096     DOI: 10.1053/euhj.2000.2314

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Predicting left ventricular recovery after replacement of a regurgitant aortic valve in pediatric and young adult patients: is it ever too late?

Authors:  Daniel A Cox; Kara Walton; Peter J Bartz; James S Tweddell; Peter C Frommelt; Michael G Earing
Journal:  Pediatr Cardiol       Date:  2012-10-09       Impact factor: 1.655

2.  Prognostic value of exercise left ventricular end-systolic volume index in patients with asymptomatic aortic regurgitation: an exercise echocardiography study.

Authors:  Yukio Sato; Masaki Izumo; Kengo Suzuki; Seisyou Kou; Kihei Yoneyama; Maya Tsukahara; Kanako Teramoto; Keisuke Minami; Shingo Kuwata; Ryo Kamijima; Kei Mizukoshi; Akio Hayashi; Sachihiko Nobuoka; Eiji Ohtaki; Tomoo Harada; Yoshihiro J Akashi
Journal:  J Echocardiogr       Date:  2016-11-21

3.  Normal ranges and physiological changes of midwall fractional shortening in healthy korean population.

Authors:  Kyungil Park; Sung-A Chang; Hyung-Kwan Kim; Hyo-Eun Park; Sang-Hoon Na; Yong-Jin Kim; Dae-Won Sohn; Byung-Hee Oh; Young-Bae Park
Journal:  Korean Circ J       Date:  2010-11-30       Impact factor: 3.243

4.  Echocardiography predicts adverse cardiac remodelling in heart failure.

Authors:  Hanumanth K Reddy; Santhosh Kg Koshy; Sanjeev Wasson; Kul B Aggarwal; Lokesh Tejwani; Alexander V Ovechkin; Suresh C Tyagi
Journal:  Exp Clin Cardiol       Date:  2004

5.  [Results of aortic valve replacement in patients with aortic stenosis associated with severe left ventricular dysfunction].

Authors:  Abderrahmane Bakkali; Imad Jaabari; Claude Koulekey Dadji; Rochde Sayah; Mohamed Laaroussi
Journal:  Pan Afr Med J       Date:  2018-01-26

6.  Prognostic factors associated with postoperative adverse outcomes in patients with aortic valve prolapse.

Authors:  Yanping Ruan; Xiaowei Liu; Xu Meng; Haibo Zhang; Yihua He
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.